{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T11:51:12Z","timestamp":1778413872574,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Kidney Foundation","award":["NKF-HCV"],"award-info":[{"award-number":["NKF-HCV"]}]},{"DOI":"10.13039\/100010995","name":"Malaysian Society Nephrology","doi-asserted-by":"publisher","award":["MSN-HCV"],"award-info":[{"award-number":["MSN-HCV"]}],"id":[{"id":"10.13039\/100010995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis C virus (HCV) infects more than 71 million people worldwide and chronic HCV infection increases the risk of liver cirrhosis and failure. Haemodialysis (HD) is one of the renal replacement therapies with risk of HCV transmission. Anti-HCV antibodies are the serological screening test for HCV infection that does not detect active phase of infection. Majority HCV infected HD patients in Malaysia do not have further HCV RNA performed due to high cost and thus HCV treatment is less frequently offered. HCV Core Antigen (HCV Ag) can potentially be used to diagnose active HCV infection in HD population in comparison to HCV RNA, at lower cost.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional study to assess the correlation between HCV Ag and HCV RNA and to identify the prevalence of active HCV infection among HCV seropositive HD patients from dialysis centres across West Malaysia from July 2019 to May 2020. Pre-dialysis blood was taken and tested for both HCV Ag and HCV RNA tests. HCV Ag was tested with Abbott ARCHITECT HCV Ag test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We recruited 112 seropositive HD patients from 17 centres with mean age of 54.04\u2009\u00b1\u200911.62\u2009years, HD vintage of 14.1\u2009\u00b1\u20099.7\u2009years, and male constitute 59.8% (67) of the study population. HCV Ag correlates well with HCV RNA (Spearman test coefficient 0.833,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The sensitivity was 90.7%, specificity 100%, positive predictive value (PPV) 100%, negative predictive value (NPV) 76.5%, and accuracy 92.9%. For HCV RNA level\u2009&gt;\u20093000\u2009IU\/mL, HCV Ag had a higher sensitivity of 95.1% and greater correlation (Spearman test coefficient 0.897, p\u2009&lt;\u20090.001). The prevalence of active HCV infection was 76.8% among HCV seropositive HD patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although HCV Ag is less sensitive, it shows an excellent correlation with HCV RNA and has 100% PPV. HCV Ag can be considered as an alternative diagnostic tool for chronic active HCV infection among HD cohort, who can then be considered for HCV treatment. For seropositive HD patient with negative HCV Ag, we recommend to follow-up with HCV RNA test.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-020-02154-4","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T12:02:47Z","timestamp":1605268967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Hepatitis C core antigen testing to diagnose active hepatitis C infection among haemodialysis patients"],"prefix":"10.1186","volume":"21","author":[{"given":"Xue Zheng","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chye Chung","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosmawati","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosnawati","family":"Yahya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubash","family":"Ganapathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soek Siam","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7589-5150","authenticated-orcid":false,"given":"Soo Kun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,13]]},"reference":[{"issue":"3","key":"2154_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"S Blach","year":"2017","unstructured":"Blach S, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161\u201376.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2154_CR2","unstructured":"World Health Organization, World Health Organization, and Replacement of (work) World Health Organization., Guidelines for the screening care and treatment of persons with chronic hepatitis C infection. https:\/\/www.who.int\/hepatitis\/publications\/hepatitis-c-guidelines-2018\/en\/."},{"issue":"3","key":"2154_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1055\/s-0038-1666841","volume":"38","author":"JV Lazarus","year":"2018","unstructured":"Lazarus JV, et al. The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations. Semin Liver Dis. 2018;38(3):181\u201392.","journal-title":"Semin Liver Dis"},{"issue":"6","key":"2154_CR4","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/j.1537-2995.2005.04390.x","volume":"45","author":"SA Glynn","year":"2005","unstructured":"Glynn SA, et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion. 2005;45(6):994\u20131002.","journal-title":"Transfusion"},{"issue":"2","key":"2154_CR5","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1053\/j.ajkd.2004.09.021","volume":"45","author":"V Sypsa","year":"2005","unstructured":"Sypsa V, et al. Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients. Am J Kidney Dis. 2005;45(2):334\u201343.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2154_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jcv.2010.02.012","volume":"48","author":"M Miedouge","year":"2010","unstructured":"Miedouge M, Saune K, Kamar N, Rieu M, Rostaing L, Izopet J. Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol. 2010;48(1):18\u201321.","journal-title":"J Clin Virol"},{"issue":"1","key":"2154_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jcv.2014.05.014","volume":"61","author":"S Chevaliez","year":"2014","unstructured":"Chevaliez S, Soulier A, Poiteau L, Bouvier-Alias M, Pawlotsky JM. Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C. J Clin Virol. 2014;61(1):145\u20138.","journal-title":"J Clin Virol"},{"issue":"3","key":"2154_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.amepre.2008.10.013","volume":"36","author":"CA Rongey","year":"2009","unstructured":"Rongey CA, Kanwal F, Hoang T, Gifford AL, Asch SM. Viral RNA testing in hepatitis C antibody-positive veterans. Am J Prev Med. 2009;36(3):235\u20138.","journal-title":"Am J Prev Med"},{"key":"2154_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jcv.2017.05.007","volume":"92","author":"FMJ Lamoury","year":"2017","unstructured":"Lamoury FMJ, et al. Hepatitis C virus core antigen: a simplified treatment monitoring tool, including for post-treatment relapse. J Clin Virol. 2017;92:32\u20138.","journal-title":"J Clin Virol"},{"issue":"5","key":"2154_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.7326\/M16-0065","volume":"165","author":"JM Freiman","year":"2016","unstructured":"Freiman JM, et al. Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: a systematic review and meta-analysis. Ann Intern Med. 2016;165(5):345\u201355.","journal-title":"Ann Intern Med"},{"issue":"8","key":"2154_CR11","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1093\/ndt\/gfq757","volume":"26","author":"I Mederacke","year":"2011","unstructured":"Mederacke I, et al. Different kinetics of HBV and HCV during haemodialysis and absence of seronegative viral hepatitis in patients with end-stage renal disease. Nephrol Dial Transplant. 2011;26(8):2648\u201356.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2154_CR12","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.kint.2018.11.038","volume":"95","author":"M Jadoul","year":"2019","unstructured":"Jadoul M, et al. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int. 2019;95(4):939\u201347.","journal-title":"Kidney Int"},{"issue":"8","key":"2154_CR13","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.ekir.2020.05.001","volume":"5","author":"PKT Li","year":"2020","unstructured":"Li PKT, et al. 2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. Kidney Int Reports. 2020;5(8):1129\u201338.","journal-title":"Kidney Int Reports"},{"issue":"2","key":"2154_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jcv.2011.11.009","volume":"53","author":"I Mederacke","year":"2012","unstructured":"Mederacke I, et al. HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis. J Clin Virol. 2012;53(2):110\u20135.","journal-title":"J Clin Virol"},{"key":"2154_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/832021","volume":"2012","author":"G Li Cavoli","year":"2012","unstructured":"Li Cavoli G, et al. Hepatitis C virus Core antigen test in monitoring of Dialysis patients. Hepat Res Treat. 2012;2012:1\u20134.","journal-title":"Hepat Res Treat"},{"issue":"1","key":"2154_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13696998.2017.1369983","volume":"21","author":"P J\u00fclicher","year":"2018","unstructured":"J\u00fclicher P, Galli C. Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting. J Med Econ. 2018;21(1):1\u201310.","journal-title":"J Med Econ"},{"key":"2154_CR17","first-page":"11","volume":"2017","author":"R Wasitthankasem","year":"2017","unstructured":"Wasitthankasem R, et al. HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs. PeerJ. 2017;2017:11.","journal-title":"PeerJ"},{"issue":"3","key":"2154_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.bjid.2012.10.028","volume":"17","author":"A Chakravarti","year":"2013","unstructured":"Chakravarti A, Chauhan MS, Dogra G, Banerjee S. Hepatitis C virus core antigen assay: can we think beyond convention in resource limited settings? Brazilian J Infect Dis. 2013;17(3):369\u201374.","journal-title":"Brazilian J Infect Dis"},{"issue":"3","key":"2154_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.eimc.2016.11.013","volume":"36","author":"R Alonso","year":"2018","unstructured":"Alonso R, P\u00e9rez-Garc\u00eda F, L\u00f3pez-Roa P, Alcal\u00e1 L, Rode\u00f1o P, Bouza E. HCV core-antigen assay as an alternative to HCV RNA quantification: a correlation study for the assessment of HCV viremia. Enferm Infecc Microbiol Clin. 2018;36(3):175\u20138.","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"8","key":"2154_CR20","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1128\/JCM.01062-15","volume":"53","author":"LT Nguyen","year":"2015","unstructured":"Nguyen LT, et al. Hepatitis C virus core mutations associated with false-negative serological results for genotype 3a core antigen. J Clin Microbiol. 2015;53(8):2697\u2013700.","journal-title":"J Clin Microbiol"},{"key":"2154_CR21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/1471-2334-14-222","volume":"14","author":"AR Garbuglia","year":"2014","unstructured":"Garbuglia AR, et al. HCV core antigen and HCV-RNA in HIV\/HCV co-infected patients with different HCV genotypes. BMC Infect Dis. 2014;14:222.","journal-title":"BMC Infect Dis"},{"key":"2154_CR22","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.2215\/CJN.01330308","volume":"3","author":"JE Trevizoli","year":"2008","unstructured":"Trevizoli JE, et al. Hepatitis C is less aggressive in hemodialysis patients than in nonuremic patients. Clin J Am Soc Nephrol. 2008;3:1385\u201390.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2154_CR23","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s12664-018-0920-3","volume":"37","author":"A Goel","year":"2018","unstructured":"Goel A, Bhadauria DS, Aggarwal R. Hepatitis C virus infection and chronic renal disease: a review. Indian J Gastroenterol. 2018;37(6):492\u2013503.","journal-title":"Indian J Gastroenterol"},{"key":"2154_CR24","doi-asserted-by":"publisher","first-page":"6701","DOI":"10.3748\/wjg.v20.i22.6701","volume":"20","author":"HL Tillmann","year":"2014","unstructured":"Tillmann HL. Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment. World J Gastroenterol. 2014;20:6701\u20136.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"2154_CR25","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1515\/cclm-2017-0754","volume":"56","author":"C Galli","year":"2018","unstructured":"Galli C, Julicher P, Plebani M. HCV core antigen comes of age: a new opportunity for the diagnosis of hepatitis C virus infection. Clin Chem Lab Med. 2018;56(6):880\u20138.","journal-title":"Clin Chem Lab Med"},{"key":"2154_CR26","first-page":"146","volume":"26","author":"E Hadziyannis","year":"2013","unstructured":"Hadziyannis E, Minopetrou M, Georgiou A, Spanou F, Koskinas J. Is HCV core antigen a reliable marker of viral load? An evaluation of HCV core antigen automated immunoassay. Ann Gastroenterol. 2013;26:146\u20139.","journal-title":"Ann Gastroenterol"},{"key":"2154_CR27","volume-title":"24th Report of the Malaysian Dialysis & Transplant 2016","author":"HS Wong","year":"2018","unstructured":"Wong HS, Goh BL. 24th Report of the Malaysian Dialysis & Transplant 2016; 2018."},{"key":"2154_CR28","unstructured":"Rahman F et al. At the Edge of a Miracle: The Hepatitis C Virus (HCV) Epidemic in Malaysia: A Situational Report. https:\/\/www.aidsdatahub.org\/resource\/edge-miracle-hcv-epidemic-malaysia-situational-report."},{"key":"2154_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/0971-4065.53324","volume":"19","author":"S Jasuja","year":"2009","unstructured":"Jasuja S, et al. Prevalence and associations of hepatitis C viremia in hemodialysis patients at a tertiary care hospital. Indian J Nephrol. 2009;19:62\u20137.","journal-title":"Indian J Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-02154-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-020-02154-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-02154-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T12:05:03Z","timestamp":1605269103000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-02154-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,13]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2154"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-02154-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-33936\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-33936\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,13]]},"assertion":[{"value":"3 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approval from the University Malaya Medical Research Ethics Committee (UMMC EC approval number: 2018128\u20135989) and National Medical Research Register (NMRR-18-2820-39944 IIR) was obtained before commencement of the study. Written consent to participate has been obtained from all patients who agreed to participate in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study does not present any competing of interest for the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"480"}}